ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results

ACADIA Pharmaceuticals (NASDAQ:ACAD) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12, FiscalAI reports. The firm had revenue of $308.00 million during the quarter, compared to analysts’ expectations of $295.51 million. ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The company’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.16 earnings per share.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

• Second-quarter revenue rose 17% to $308 million on an adjusted basis, driven by strong demand for both DAYBUE and NUPLAZID.
• DAYBUE sales increased 30% to $125 million, with DAYBUE STIX adopted by approximately 40% of U.S. patients by quarter-end and helping bring discontinued patients back to treatment. ACADIA raised its 2026 DAYBUE guidance to $480 million–$510 million.
• NUPLAZID sales grew 10% to $183 million, while new patient prescriptions rose 20% year over year. Management said the expanded field force is beginning to contribute and maintained its goal of approximately $1 billion in 2028 NUPLAZID sales.
• DAYBUE received a positive CHMP opinion in Europe, with a European Commission decision expected by the end of the third quarter and a planned German launch in early fourth quarter. Management expects Europe to represent less than half of its $700 million 2028 DAYBUE sales target.
• The key pipeline catalyst is the phase II RADIANT readout for remlifanserin in Alzheimer’s disease psychosis, now expected in September–October after enrollment of 363 patients. ACADIA has begun phase III screening, but the program remains dependent on demonstrating clinically meaningful efficacy and a supportive safety profile.

ACADIA Pharmaceuticals Price Performance

ACAD stock opened at $27.15 on Wednesday. The business has a fifty day moving average price of $23.95 and a 200 day moving average price of $23.20. ACADIA Pharmaceuticals has a fifty-two week low of $19.69 and a fifty-two week high of $28.35. The stock has a market capitalization of $4.65 billion, a price-to-earnings ratio of 12.34, a P/E/G ratio of 17.76 and a beta of 0.81.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ACAD shares. Bank of America reissued a “buy” rating and issued a $14.50 target price on shares of ACADIA Pharmaceuticals in a report on Wednesday, July 29th. Royal Bank Of Canada upped their price target on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. HC Wainwright lowered ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, June 29th. Thirteen equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $32.31.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, insider James Kihara sold 5,401 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the transaction, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. The trade was a 18.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the sale, the executive vice president owned 18,994 shares in the company, valued at $496,313.22. The trade was a 46.57% decrease in their position. The disclosure for this sale is available in the SEC filing. 26.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. raised its stake in shares of ACADIA Pharmaceuticals by 14.5% in the fourth quarter. Invesco Ltd. now owns 847,961 shares of the biopharmaceutical company’s stock worth $22,649,000 after acquiring an additional 107,386 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $257,000. Mackenzie Financial Corp increased its holdings in shares of ACADIA Pharmaceuticals by 7.3% in the fourth quarter. Mackenzie Financial Corp now owns 57,274 shares of the biopharmaceutical company’s stock valued at $1,526,000 after purchasing an additional 3,917 shares in the last quarter. Virtus Investment Advisers LLC raised its position in ACADIA Pharmaceuticals by 23.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 25,170 shares of the biopharmaceutical company’s stock worth $672,000 after purchasing an additional 4,729 shares during the last quarter. Finally, Sphera Funds Management LTD. raised its position in ACADIA Pharmaceuticals by 42.5% in the 4th quarter. Sphera Funds Management LTD. now owns 212,202 shares of the biopharmaceutical company’s stock worth $5,668,000 after purchasing an additional 63,302 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.